Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias
about
The FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactionsTyrosine kinase inhibitors targeting FLT3 in the treatment of acute myeloid leukemia.FLT3 Internal Tandem Duplication and D835 Mutations in Patients with Acute Lymphoblastic Leukemia and its Clinical SignificanceFLT3 mutations in canine acute lymphocytic leukemiaThe Cytokine Flt3-Ligand in Normal and Malignant HematopoiesisThe AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice.Mobilization of CD34+ progenitor cells in association with decreased proliferation in the bone marrow of macaques after administration of the Fms-like tyrosine kinase 3 ligand.Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.The Biology and Targeting of FLT3 in Pediatric Leukemia.FLT3-regulated antigens as targets for leukemia-reactive cytotoxic T lymphocytes.LFA-1 on leukemic cells as a target for therapy or drug delivery.MicroRNA-16 is down-regulated in mutated FLT3 expressing murine myeloid FDC-P1 cells and interacts with Pim-1.FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitorsIncorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens.Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia.FLT3/ITD AML and the law of unintended consequences.Further activation of FLT3 mutants by FLT3 ligandNovel agents for the treatment of childhood acute leukemia.miR-590-5p, miR-219-5p, miR-15b and miR-628-5p are commonly regulated by IL-3, GM-CSF and G-CSF in acute myeloid leukemia.Targeted Therapy of FLT3 in Treatment of AML-Current Status and Future Directions.A phase I study of midostaurin and azacitidine in relapsed and elderly AML patientsInternal tandem duplications of the FLT3 gene are present in leukemia stem cellsFLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia.Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML.Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8)Fms-like tyrosine kinase (FLT) 3 and FLT3 internal tandem duplication in different types of adult leukemia: analysis of 147 patientsRecent advances and novel agents for FLT3 mutated acute myeloid leukemia.Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.Targeting FLT3 for the treatment of leukemiaMechanisms of resistance to FLT3 inhibitors.FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation.Novel targeted drug therapies for the treatment of childhood acute leukemiaHow I treat FLT3-mutated AML.Bench to bedside targeting of FLT3 in acute leukemia.The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond.RNA binding protein MSI2 positively regulates FLT3 expression in myeloid leukemia.Development and Characterization of FLT3-Specific Curcumin-Loaded Polymeric Micelles as a Drug Delivery System for Treating FLT3-Overexpressing Leukemic Cells.FLT3 signals via the adapter protein Grb10 and overexpression of Grb10 leads to aberrant cell proliferation in acute myeloid leukemiaMechanisms of Resistance to FLT3 Inhibitors and the Role of the Bone Marrow Microenvironment.FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations.
P2860
Q28535342-E7BDDD59-1267-43DA-B746-900911B4FD7CQ33767026-BC37A067-294B-4B4A-8E2B-6165F943E4CEQ33778374-269A0E6D-1572-417E-A03A-907B49EB7804Q33805426-1884010F-9925-4F93-9212-2238D5EB3288Q33838356-AE1CC65C-2795-45C4-AB50-A0809937354CQ33895709-12B4189D-5413-4908-977F-3605C17762D4Q34044928-9431DE58-7232-4079-BA39-12127C8A0241Q34095013-E8D9110B-80E2-4AEC-BD46-112BD8CC4537Q34229555-9F2A56C4-8ADA-4C08-8577-A840EEAD1FEEQ34350591-32B3A273-9EC0-4C62-8DDB-B2ECAE5C315EQ34394850-E8449D58-BE2F-4884-B70C-0784BA268C79Q34412520-75CD0328-F8F6-4B92-89D6-CD2BC121F2ECQ34566158-17A102FE-C1B2-4462-A10C-A46243406747Q34591403-D8D98E1E-3664-472A-ACAB-E1424E96C692Q35125923-5B2CA1B5-3707-4210-A4F5-9E91073EDB33Q35127958-7E8A6AFA-5495-4BAF-85D9-F54F102081A1Q35163307-E272EF18-0C96-48B5-A869-1DAC1D7C26E5Q35192790-5AE8E33D-B3B0-454C-A3D7-D2DDD6ACEA24Q35690892-BDC63D9C-5197-4792-AF4D-5B2592B7DBCCQ35750567-DD19B9BD-7175-4711-8DCD-44E1E1DA5367Q35793176-67F25D8D-9062-4C02-A32A-1E2AF81C010AQ35847990-22342222-EE1D-4FC0-B735-3082FBA0DAD6Q36183556-B660090F-C70A-49E9-A1E4-E7570D413E0BQ36410157-58242CC9-0B85-4A1B-837E-3FCEDAD986A6Q36447920-324F7AB2-D47A-4603-B97B-04C08B67452EQ36971233-70B8B15B-6B03-4ECE-8135-0F9A7E5270BDQ37043763-04E44B66-A160-42F4-8E81-657C1B163CEBQ37244802-21A7A621-B5A6-4397-9C32-7398A196B32DQ37257308-33301124-50DD-4727-BB25-1951CFA46372Q37375423-D99A084A-7422-4105-8180-DD4133E28D78Q37460343-827CE25D-1652-45C0-A455-5E4E7FA8D74BQ37477482-851B969B-6014-43BC-A9A5-5AF9CC31DE29Q37623389-E4C48B9E-5321-484B-9D63-3854F765B889Q37724957-5CBAB0CF-AA54-4B46-BA05-A7547FA512B8Q38216649-9F846147-21AA-4152-8D86-AA0BF9DFD6E8Q38720331-A2585308-6D78-41E5-AB16-610E6ECC7721Q38810295-C0DE6112-82D2-44F6-A948-98CAE5B2B826Q39225058-03714946-D7A3-4D23-96CC-0DF2EC2269B3Q39411949-757A87E2-9307-423B-810E-47D8D6EED2D1Q39513601-AADEFF65-F769-4046-AFA6-505449FC7322
P2860
Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias
description
im Februar 1996 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 February 1996
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в лютому 1996
@uk
name
Expression of the hematopoieti ...... STK-1/Flk2) in human leukemias
@en
Expression of the hematopoietic growth factor receptor FLT3
@nl
type
label
Expression of the hematopoieti ...... STK-1/Flk2) in human leukemias
@en
Expression of the hematopoietic growth factor receptor FLT3
@nl
prefLabel
Expression of the hematopoieti ...... STK-1/Flk2) in human leukemias
@en
Expression of the hematopoietic growth factor receptor FLT3
@nl
P2093
P1433
P1476
Expression of the hematopoieti ...... STK-1/Flk2) in human leukemias
@en
P2093
Borowitz MJ
Levenstein M
Rockwell P
P304
P407
P577
1996-02-01T00:00:00Z